C4 Therapeutics appoints Owen Hughes to board of directors

C4 Therapeutics, Inc.

Owen Hughes appointed as Class I director, term until 2024 annual meeting.
Hughes co-founded Cullinan Oncology, raised over $400M in IPO, served as CEO.
Received options for 52,000 shares vesting over three years under 2020 plan.
Indemnification agreement entered in same form as other directors.
Hughes also chairs XOMA, Ikena Oncology; previously on boards of Radius, Translate Bio.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Owen P. Hughes, Jr.

Director

CCCC · C4 Therapeutics, Inc.

Effective: 2023-11-16
Filed: November 20, 2023, 6:59 PM ET

On November 16, 2023, the Board of Directors (the “ Board ”) of C4 Therapeutics, Inc. (the “ Company ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Owen P. Hughes, Jr. as a director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Owen P. Hughes, Jr. was appointed as Director at C4 Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On November 16, 2023, the Board of Directors (the “ Board ”) of C4 Therapeutics, Inc. (the “ Company ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Owen P. Hughes, Jr. as a director of the Company.

View on SEC.gov

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-039562

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.